International Vaccine Institute (IVI)’s Post

IVI is proud to participate in the World Vaccine Congress EU 2025, where we presented a bold vision for global health innovation through the Korean ARPA-H (Advanced Research Projects Agency for Health) initiative. In collaboration with the K-Health MIRAE (Medical Innovation Research And Evolution) team, we’re driving mission-oriented R&D to address some of the world’s most pressing health challenges—from pandemic preparedness to rare disease solutions. Our joint efforts under the Korean ARPA-H framework, a key pillar of the K-Health MIRAE initiative, aim to revolutionize vaccine development, accelerate biotech breakthroughs, and enhance global health security. Supported by Korea's Ministry of Health and Welfare and KHIDI, this partnership reflects IVI’s commitment to pioneering decentralized vaccine manufacturing and ultra-rapid mRNA platforms. The model of a mobile manufacturing unit pictured is an innovative system designed to produce up to 1 million doses of mRNA vaccines within 100 days—enabling rapid response during the early stages of a pandemic.  Let’s shape the future of global health—through the power of partnership and innovation.